Biomolecules to Biomarkers? U87MG Marker Evaluation on the Path towards Glioblastoma Multiforme Pathogenesis.
Biomarker
Eker rats
GAS5
GBM
Glioma
ICAM-1
PARTICLE
U87MG
lncRNA
prominin-1
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
received:
07
12
2023
revised:
10
01
2024
accepted:
12
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
The heterogeneity of the glioma subtype glioblastoma multiforme (GBM) challenges effective neuropathological treatment. The reliance on in vitro studies and xenografted animal models to simulate human GBM has proven ineffective. Currently, a dearth of knowledge exists regarding the applicability of cell line biomolecules to the realm of GBM pathogenesis. Our study's objectives were to address this preclinical issue and assess prominin-1, ICAM-1,
Identifiants
pubmed: 38258133
pii: pharmaceutics16010123
doi: 10.3390/pharmaceutics16010123
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Charles University
ID : COOPERATIO: the scientific project "Medical Diagnostics and Basic Medical Sciences" (in the field "Medical Genetics"), grant number 207036
Organisme : Charles University
ID : neurology SVV grant 260648/SVV/2023: Research of drug addiction and neuropsychiatric diseases - from the basic research to the clinical practice.